PreveCol®
A simple way to stay ahead of colon cancer

What is PreveCol®?

It is a service for the early detection of colorectal cancer through a blood sample.

Don't wait until you have symptoms and it's too late.

 At Amadix we provide you with access to this innovative service through our 

ACCESS TO PREVECOL ®
  • A simple blood test to detect cancer

A new non-invasive way to access early detection of colorectal cancer without complications and prior preparations 

  • Increasing survival

By identifying cancer early, PreveCol impacts survival. When cancer is diagnosed in early stages (I-II), the probability of survival at 5 years is 90%, however, when cancer is diagnosed in advanced stages, survival drops dramatically to 14%1.

  • The importance of screening for precancerous lesions or advanced adenomas

In addition to cancer screening, it is important to monitor for precancerous lesions, also called advanced adenomas, in order to stay ahead of cancer.

You have two options to access our colon cancer screening service.

opción 1: comprar test en nuestra web

Pasos para acceder a PreveCol® a través de nuestra web

1

Purchase PreveCol®

Access the PreveCol® purchase on our online platform.

2

Check your e-mail

Once you have paid for the service, we will send you the instructions by email.

3

Have your blood sample taken

Go to one of the approved collaborating laboratories to have your blood taken (see the list). There they will take your blood sample, which will be used to analyse the biomarkers of colorectal cancer or precancerous lesions.

4

Receive your result

The result report will be sent to your email address within 5 weeks.

Note: in case of a positive result, the report will be delivered with the possibility of having a video consultation with a health professional, who will clarify any doubts regarding the result report and will provide guidance on the following steps

ACCESS TO PREVECOL ®
opción 1: comprar test en nuestra web

Steps to access PreveCol® through our website

ACCESS TO PREVECOL ®

1

Purchase PreveCol®

Access the PreveCol® purchase on our online platform.

2

Check your e-mail

Once you have paid for the service, we will send you the instructions by email.

3

Have your blood sample taken

Go to one of the approved collaborating laboratories to have your blood taken (see the list). There they will take your blood sample, which will be used to analyse the biomarkers of colorectal cancer or precancerous lesions.

4

Receive your result

The result report will be sent to your email address within 5 weeks. 

Note: in case of a positive result, the report will be delivered with the possibility of having a video consultation with a health professional, who will clarify any doubts regarding the result report and will provide guidance on the following steps

mujer sonriendo
opción 2: acudir a un centro privado colaborador

Another way to access PreveCol®

You can also go to a medical centre where they will make all the necessary arrangements, if you prefer.

We can help you find the nearest medical centre. Call +34 637 899 152 or write an email to test@amadix.com

CONTACT

How does our colon and rectal cancer screening service work?

Transforming the early detection of cancer

is an innovative solution to stay ahead of colorectal cancer, offering one of the best results on the market in the early detection of cancer and advanced adenomas or precancerous lesions, which are key in the prevention of colorectal cancer.

Simple, effective, fast and without prior preparation.

High potential

Superior precision

Very simple

Without prior preparation

Reliable

Disruptive

PreveCol® Characteristics

An innovative blood test service for the early detection of colorectal cancer that can be performed in any of the wide network of collaborating, approved laboratories and you can also purchase the service through our website 

PreveCol® is indicated for women and men aged 50-75 years who are at average risk of colorectal cancer.

Overall, the lifetime risk of colorectal cancer is approximately 1 in 23 for men and 1 in 25 for women. However, each person’s risk may be higher or lower than this, depending on their risk factors for colorectal cancer.(1)

When colon cancer is detected at early, localised stages, the 5-year survival rate is 90%, while this rate drops to 14%1 when patients are diagnosed at advanced stages. These data demonstrate the importance of detecting colon cancer at a stage where it is still treatable.
5-year survival rate

 

5-year survival rate

Diagnosed in stage I and II

cancer de colon supervicencia

9 out of 10 survive 5 years

PreveCol allows the identification of advanced adenomas or pre-cancerous lesions, which are precursors to cancer.
Thanks to PreveCol®, we can identify the possible presence of these precancerous lesions. At the end of the service, you will receive a results report which will tell you whether there is a possibility of having premalignant lesions and/or colon cancer.
A positive result will indicate the possible presence of colorectal cancer and/or advanced adenomas (precancerous lesions). In this case, the patient will be advised to go to their health centre and undergo a colonoscopy diagnostic test.
Finding and removing premalignant lesions and proceeding to excision (endoscopic polypectomy) prevents colon cancer.

 
 

(*PreveCol is not a substitute test for colonoscopy. In case of a positive test result, a colonoscopy should be performed)

Yes, the process you need to follow is minimally invasive as it only requires a simple blood draw at one of Amadix’s accredited collection centres. PreveCol has advantages over other screening methods, such as those based on direct visualisation of the colorectal area (colonoscopy), which is an invasive method and, although the possibility of complications such as perforation of the bowel are rare, they could seriously harm patients if they occur*. 

It also has advantages over the faecal occult blood test. On the one hand, a blood test is simpler, avoiding the manipulation of faeces. On the other hand, PreveCol is more sensitive in the detection of precancerous lesions .

(*PreveCol is not a substitute test for colonoscopy. In case of a positive test result, a colonoscopy should be performed)

 

FDA - Breakthrough Device Designation

¿Por qué se le ha dado a PreveCol® esta designación de Breakthrough Device?

Para la prestación del servicio, Amadix emplea Prevecol®, software de diagnóstico in vitro que ha recibido en diciembre de 2023, la designación de prueba innovadora (Breakthrough Device Designation) por parte de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA).

Para obtener esta distinción, PreveCol® ha demostrado una mayor eficacia en la detección temprana de lesiones precancerosas de cáncer colorrectal que las pruebas disponibles en Estados Unidos, lo que supone un beneficio significativo para los pacientes.

¿Qué significa para Amadix y para PreveCol®?

Amadix se convierte en la primera empresa europea en anunciar la obtención de la designación de Breakthrough Device de la FDA para la detección temprana de cáncer colorrectal.

Si necesitas más información puedes contactarnos en:
test@amadix.com

Colorectal cancer is the third most common tumor and is usually detected in late stages.

1 926 425

New cases of colorectal cancer worldwide in 20221

Year 2022

1,926M

Year 2020

1,880M

Colon cancer estimate 2022-2045

It is estimated that colorectal cancer will continue to increase in the coming years. By 2045, there could be around 3.2 million new cases per year worldwide, an increase of 70%. In addition, annual deaths from the disease could reach 1.6 million, 83% more than today. 1

estimación cancer de colon 2045

How did we develop the colon cancer test, PreveCol®?

Developing algorithms with Artificial Intelligence for early cancer diagnosis

PreveCol has been fully developed and validated by Amadix. Through case-control and prospective clinical trials conducted in Spain, Poland and Germany.

The data obtained from these clinical trials have facilitated the approval of the in vitro diagnostic software used by Amadix by the European and Spanish regulatory authorities, thus allowing the commercialisation of the PreveCol® service.

What developments is Amadix making in its early detection tests?

At Amadix we are working on developing algorithms that lead to early diagnosis of cancer.

In addition, we are performing risk factor analysis, using Artificial Intelligence and Big Data from medical history and individual habits.

Thanks to these technologies, we can identify hidden risks, develop predictive models and incorporate these advances into algorithms. This allows us to define new screening populations beyond the age criterion, thus contributing to earlier diagnosis and better quality of life for patients.

Request PreveCol®

You can access the PreveCol® service via our website. You can also ask your doctor.

If you need additional information, you can contact us at:

ACCESS THE SERVICE THROUGH OUR WEB SITE

I am a doctor and I want to incorporate PreveCol® in my clinic.

f you are a doctor and would like to incorporate PreveCol in your medical practice, please contact us by filling in this form or send us an e-mail to test@amadix.com.







    I have read and accept the Privacy policy

    This site is protected by Google's reCaptcha and its Privacy Policy and Terms of Service apply.

    Sources:

    1 Key Statistics for Colorectal Cancer
    (cancer.org)

    Amadix